Ville Hällberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ville Hällberg has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ari Palomäki
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
4 shared publications - Matti Kataja
National Institute for Health and Welfare, Helsinki, Finland
2 shared publications - Matti Tarkka
Tampere University Hospital, Tampere, Finland
2 shared publications Jorma Lahtela
Medical School, University of Tampere, Finland
1 shared publication- Jorma Lahtela
Tampere University Hospital, Tampere, Finland
1 shared publication - K. Malminiemi
Medical School, University of Tampere, Tampere, Finland
1 shared publication
Latest Publications
- Open Access
- 26 July 2016
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 15 (1) , 124
Prompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital
The long-term success of coronary artery bypass grafting (CABG) depends on secondary prevention. Vast evidence provided by the results of cholesterol mega-trials over two decades has shown that effective reduction of LDL cholesterol improves the prognosis of patients with coronary heart disease. However, the implementation of these results into the clinical practice has turned out to be challenging. We analysed how the information derived from clinical statin trials and international recommendations affected the local treatment practices of dyslipidaemia of CABG patients during a 20-year time period. The cohort includes all CABG patients (n = 953) treated in Kanta-Häme Central Hospital during the time period 1990–2009. At the postoperative visits in the cardiology outpatient clinic, each patient’s statin prescription was recorded, and blood lipids were determined. During 1990–1994, 12.0 % of patients were on statins and during the following 5-year time periods the proportion was 57.2, 82.2 and 96.8 %, respectively. During the 20-year observation period (1990–2009), the effective statin dose increased progressively during these 5-year periods up to 36-fold, while the mean concentration of LDL cholesterol decreased from 3.7 to 2.1 mmol/l and that of apolipoprotein B from 1.3 to 0.8 g/l. In the very last year of follow-up, the mean concentrations of LDL-C and apoB were 1.83 mmol/l and 0.78 g/l, respectively. The most prominent increase in statin use and dosage took place during 1994–1996 and 2003–2005, respectively. Among CABG patients the lipid-lowering efficacy of statin therapy improved dramatically since 1994. This progress was accompanied by significant and favourable changes of lipid and apolipoprotein-B values. This study shows that it is possible to effectively improve lipid treatment policy once the results of relevant trials are available, and that this may happen even before international or national guidelines have been updated.
- 26 July 2016
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 15 (1) , 124
Open AccessPrompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital
The long-term success of coronary artery bypass grafting (CABG) depends on secondary prevention. Vast evidence provided by the results of cholesterol mega-trials over two decades has shown that effective reduction of LDL cholesterol improves the prognosis of patients with coronary heart disease. However, the implementation of these results into the clinical practice has turned out to be challenging. We analysed how the information derived from clinical statin trials and international recommendations affected the local treatment practices of dyslipidaemia of CABG patients during a 20-year time period. The cohort includes all CABG patients (n = 953) treated in Kanta-Häme Central Hospital during the time period 1990–2009. At the postoperative visits in the cardiology outpatient clinic, each patient’s statin prescription was recorded, and blood lipids were determined. During 1990–1994, 12.0 % of patients were on statins and during the following 5-year time periods the proportion was 57.2, 82.2 and 96.8 %, respectively. During the 20-year observation period (1990–2009), the effective statin dose increased progressively during these 5-year periods up to 36-fold, while the mean concentration of LDL cholesterol decreased from 3.7 to 2.1 mmol/l and that of apolipoprotein B from 1.3 to 0.8 g/l. In the very last year of follow-up, the mean concentrations of LDL-C and apoB were 1.83 mmol/l and 0.78 g/l, respectively. The most prominent increase in statin use and dosage took place during 1994–1996 and 2003–2005, respectively. Among CABG patients the lipid-lowering efficacy of statin therapy improved dramatically since 1994. This progress was accompanied by significant and favourable changes of lipid and apolipoprotein-B values. This study shows that it is possible to effectively improve lipid treatment policy once the results of relevant trials are available, and that this may happen even before international or national guidelines have been updated.
- 24 February 2016
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 6 (8) , 771-777
Obesity paradox disappears in coronary artery bypass graft patients during 20-year follow-up
Although obesity is a risk factor for coronary heart disease (CHD), it might be associated with a favourable prognosis in patients with CHD. The aim of the study was to evaluate this so called ‘obesity paradox’ during a follow-up period of 20 years in patients who had undergone coronary artery bypass grafting (CABG). The study population consisted of 922 CHD patients who had undergone CABG between 1993 and 1994. Pre and perioperative data was collected from patient records and supplemented with patient questionnaires, telephone contacts and data from national archives. The 10-year postoperative prognosis of normal-weight patients (body mass index (BMI) 18.5–24.9 kg/m2) was inferior to that of overweight (BMI 25.0–29.9 kg/m2) and obese patients (BMI⩾30.0 kg/m2) and to the background population. Beyond 10 years the prognosis of obese patients deteriorated when compared with the overweight group. At the end of the 20-year follow-up, survival of the normal weight group was 0.68 (95% confidence interval (CI), 0.49–0.87; pppp<0.01). During long-term follow-up the obesity paradox seems to disappear due to progression of cardiometabolic disease in patients who have undergone CABG.
- 24 February 2016
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 6 (8) , 771-777
Obesity paradox disappears in coronary artery bypass graft patients during 20-year follow-up
Although obesity is a risk factor for coronary heart disease (CHD), it might be associated with a favourable prognosis in patients with CHD. The aim of the study was to evaluate this so called ‘obesity paradox’ during a follow-up period of 20 years in patients who had undergone coronary artery bypass grafting (CABG). The study population consisted of 922 CHD patients who had undergone CABG between 1993 and 1994. Pre and perioperative data was collected from patient records and supplemented with patient questionnaires, telephone contacts and data from national archives. The 10-year postoperative prognosis of normal-weight patients (body mass index (BMI) 18.5–24.9 kg/m2) was inferior to that of overweight (BMI 25.0–29.9 kg/m2) and obese patients (BMI⩾30.0 kg/m2) and to the background population. Beyond 10 years the prognosis of obese patients deteriorated when compared with the overweight group. At the end of the 20-year follow-up, survival of the normal weight group was 0.68 (95% confidence interval (CI), 0.49–0.87; pppp<0.01). During long-term follow-up the obesity paradox seems to disappear due to progression of cardiometabolic disease in patients who have undergone CABG.
- Open Access
- 1 January 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 25
Associations of metabolic syndrome and diabetes mellitus with 16-year survival after CABG
The associations of metabolic syndrome (MetS) or diabetes mellitus (DM) on long-term survival after coronary artery bypass grafting (CABG) have not been extensively evaluated. The aim of the present study was to assess the impact of MetS and DM on the 16-year survival after CABG.
- 1 January 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 25
Open AccessAssociations of metabolic syndrome and diabetes mellitus with 16-year survival after CABG
The associations of metabolic syndrome (MetS) or diabetes mellitus (DM) on long-term survival after coronary artery bypass grafting (CABG) have not been extensively evaluated. The aim of the present study was to assess the impact of MetS and DM on the 16-year survival after CABG.
- Open Access
- 29 January 2009
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 4 (1) , 6
Retention of work capacity after coronary artery bypass grafting. A 10-year follow-up study
- 29 January 2009
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 4 (1) , 6
Open AccessRetention of work capacity after coronary artery bypass grafting. A 10-year follow-up study